Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens. 2021

D Hirt, and M Oualha, and B Pasquiers, and S Blanot, and R Rubinstazjn, and C Glorion, and S El Messaoudi, and D Drummond, and V Lopez, and J Toubiana, and A Béranger, and Sana Boujaafar, and Yi Zheng, and Carmen Capito, and S Winter, and P L Léger, and R Berthaud, and Inès Gana, and F Foissac, and J M Tréluyer, and N Bouazza, and S Benaboud
EA7323, Evaluation des Thérapeutiques et Pharmacologie Périnatale et Pédiatrique, Université de Paris, 89 rue d'Assas, 75014, Paris, France. deborah.hirt@aphp.fr.

OBJECTIVE This study aimed to characterize pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing scheme. METHODS Children treated with ciprofloxacin were included. Pharmacokinetics were described using non-linear mixed-effect modelling and validated with an external dataset. Monte Carlo simulations investigated dosing regimens to achieve a target AUC0-24 h/MIC ratio ≥ 125. RESULTS A total of 189 children (492 concentrations) were included. A two-compartment model with first-order absorption and elimination best described the data. An allometric model was used to describe bodyweight (BW) influence, and effects of estimated glomerular filtration rate (eGFR) and age were significant on ciprofloxacin clearance. CONCLUSIONS The recommended IV dose of 10 mg/kg q8h, not exceeding 400 mg q8h, would achieve AUC0-24 h to successfully treat bacteria with MICs ≤ 0.25 (e.g. Salmonella, Escherichia coli, Proteus, Haemophilus, Enterobacter, and Klebsiella). A dose increase to 600 mg q8h in children > 40 kg and to 15 mg/kg q8h (max 400 mg q8h, max 600 mg q8h if augmented renal clearance, i.e., eGFR > 200 mL/min/1.73 m2) in children < 40 kg would be needed for the strains with highest MIC (16% of Pseudomonas aeruginosa and 47% of Staphylococcus aureus). The oral recommended dose of 20 mg/kg q12h (not exceeding 750 mg) would cover bacteria with MICs ≤ 0.125 but may be insufficient for bacteria with higher MIC and a dose increase according bodyweight and eGFR would be needed. These doses should be prospectively confirmed, and a therapeutic drug monitoring could be used to refine them individually.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D009010 Monte Carlo Method In statistics, a technique for numerically approximating the solution of a mathematical problem by studying the distribution of some random variable, often generated by a computer. The name alludes to the randomness characteristic of the games of chance played at the gambling casinos in Monte Carlo. (From Random House Unabridged Dictionary, 2d ed, 1993) Method, Monte Carlo
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001827 Body Height The distance from the sole to the crown of the head with body standing on a flat surface and fully extended. Body Heights,Height, Body,Heights, Body
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children

Related Publications

D Hirt, and M Oualha, and B Pasquiers, and S Blanot, and R Rubinstazjn, and C Glorion, and S El Messaoudi, and D Drummond, and V Lopez, and J Toubiana, and A Béranger, and Sana Boujaafar, and Yi Zheng, and Carmen Capito, and S Winter, and P L Léger, and R Berthaud, and Inès Gana, and F Foissac, and J M Tréluyer, and N Bouazza, and S Benaboud
July 2014, European journal of clinical pharmacology,
D Hirt, and M Oualha, and B Pasquiers, and S Blanot, and R Rubinstazjn, and C Glorion, and S El Messaoudi, and D Drummond, and V Lopez, and J Toubiana, and A Béranger, and Sana Boujaafar, and Yi Zheng, and Carmen Capito, and S Winter, and P L Léger, and R Berthaud, and Inès Gana, and F Foissac, and J M Tréluyer, and N Bouazza, and S Benaboud
March 2017, The Journal of antimicrobial chemotherapy,
D Hirt, and M Oualha, and B Pasquiers, and S Blanot, and R Rubinstazjn, and C Glorion, and S El Messaoudi, and D Drummond, and V Lopez, and J Toubiana, and A Béranger, and Sana Boujaafar, and Yi Zheng, and Carmen Capito, and S Winter, and P L Léger, and R Berthaud, and Inès Gana, and F Foissac, and J M Tréluyer, and N Bouazza, and S Benaboud
October 2011, The Journal of antimicrobial chemotherapy,
D Hirt, and M Oualha, and B Pasquiers, and S Blanot, and R Rubinstazjn, and C Glorion, and S El Messaoudi, and D Drummond, and V Lopez, and J Toubiana, and A Béranger, and Sana Boujaafar, and Yi Zheng, and Carmen Capito, and S Winter, and P L Léger, and R Berthaud, and Inès Gana, and F Foissac, and J M Tréluyer, and N Bouazza, and S Benaboud
May 1993, The Journal of antimicrobial chemotherapy,
D Hirt, and M Oualha, and B Pasquiers, and S Blanot, and R Rubinstazjn, and C Glorion, and S El Messaoudi, and D Drummond, and V Lopez, and J Toubiana, and A Béranger, and Sana Boujaafar, and Yi Zheng, and Carmen Capito, and S Winter, and P L Léger, and R Berthaud, and Inès Gana, and F Foissac, and J M Tréluyer, and N Bouazza, and S Benaboud
May 2005, The oncologist,
D Hirt, and M Oualha, and B Pasquiers, and S Blanot, and R Rubinstazjn, and C Glorion, and S El Messaoudi, and D Drummond, and V Lopez, and J Toubiana, and A Béranger, and Sana Boujaafar, and Yi Zheng, and Carmen Capito, and S Winter, and P L Léger, and R Berthaud, and Inès Gana, and F Foissac, and J M Tréluyer, and N Bouazza, and S Benaboud
April 1987, The American journal of medicine,
D Hirt, and M Oualha, and B Pasquiers, and S Blanot, and R Rubinstazjn, and C Glorion, and S El Messaoudi, and D Drummond, and V Lopez, and J Toubiana, and A Béranger, and Sana Boujaafar, and Yi Zheng, and Carmen Capito, and S Winter, and P L Léger, and R Berthaud, and Inès Gana, and F Foissac, and J M Tréluyer, and N Bouazza, and S Benaboud
October 2018, Antimicrobial agents and chemotherapy,
D Hirt, and M Oualha, and B Pasquiers, and S Blanot, and R Rubinstazjn, and C Glorion, and S El Messaoudi, and D Drummond, and V Lopez, and J Toubiana, and A Béranger, and Sana Boujaafar, and Yi Zheng, and Carmen Capito, and S Winter, and P L Léger, and R Berthaud, and Inès Gana, and F Foissac, and J M Tréluyer, and N Bouazza, and S Benaboud
April 1986, European journal of clinical microbiology,
D Hirt, and M Oualha, and B Pasquiers, and S Blanot, and R Rubinstazjn, and C Glorion, and S El Messaoudi, and D Drummond, and V Lopez, and J Toubiana, and A Béranger, and Sana Boujaafar, and Yi Zheng, and Carmen Capito, and S Winter, and P L Léger, and R Berthaud, and Inès Gana, and F Foissac, and J M Tréluyer, and N Bouazza, and S Benaboud
November 1998, Biopharmaceutics & drug disposition,
D Hirt, and M Oualha, and B Pasquiers, and S Blanot, and R Rubinstazjn, and C Glorion, and S El Messaoudi, and D Drummond, and V Lopez, and J Toubiana, and A Béranger, and Sana Boujaafar, and Yi Zheng, and Carmen Capito, and S Winter, and P L Léger, and R Berthaud, and Inès Gana, and F Foissac, and J M Tréluyer, and N Bouazza, and S Benaboud
December 2001, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!